Biomarin Pharmaceutical (BMRN) Receivables (2009 - 2026)

Biomarin Pharmaceutical has disclosed Receivables across 18 years of filings, most recently posting $903.9 million for Q1 2026.

• Quarterly Receivables rose 22.29% year-over-year to $903.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $903.9 million (up 22.29% YoY) and the FY2025 annual result came in at $908.2 million, up 37.5% from the prior year.
• Receivables held at $903.9 million in Q1 2026, from $908.2 million in the prior quarter.
• Over five years, Receivables peaked at $908.2 million in Q4 2025 and troughed at $419.6 million in Q3 2022.
• A 5-year average of $656.2 million and a median of $637.2 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables jumped 39.0% — and 2025, when it advanced 1.64%.
• Tracing BMRN's Receivables over 5 years: stood at $461.3 million in 2022, then soared by 37.37% to $633.7 million in 2023, then grew by 4.23% to $660.5 million in 2024, then jumped by 37.5% to $908.2 million in 2025, then decreased by 0.47% to $903.9 million in 2026.
• Business Quant data shows BMRN's Receivables at $903.9 million in Q1 2026, $908.2 million in Q4 2025, and $790.3 million in Q3 2025.